HOOKIPA Pharma Grants Inducement Award to Chief Development Officer Mark Winderlich
The Compensation Committee of HOOKIPA Pharma Inc.has approved the grant of non-statutory options to Mark Winderlich, the newly appointed Chief Development Officer of the company.Winderlich will have the opportunity to purchase an aggregate of 250,000 shares of the company’s Common Stock under HOOKIPA’s 2023 Inducement Plan.This inducement award is in accordance with Nasdaq Listing Rule 5635(c)(4) and is intended to incentivize Winderlich’s acceptance of employment with HOOKIPA.
The options have an exercise price of $0.76 per share and a ten-year term, with vesting over four years.25% of the options will vest on the one-year anniversary of the grant date, and the remaining will vest in equal quarterly installments for the following three years, contingent upon Winderlich’s continued service with HOOKIPA on each vesting date.
This announcement comes on the heels of HOOKIPA’s recent equity investment from Gilead Sciences, where Gilead purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million.With a total of 94.86 million shares outstanding and a current price of $0.76, HOOKIPA continues to make strategic moves to drive its immunotherapeutics development forward.
In conclusion, the grant of an inducement award to Mark Winderlich highlights HOOKIPA’s commitment to attracting top talent and positioning itself for future growth in the immunotherapeutics space.
Comments